STEMCENTRX
Stemcentrx develops therapies that cure and significantly improve survival for cancer patients. It provides disease specific treatments that attack tumors at the roots. Brian Slingerland and Scott J. Dylla founded Stemcentrx in 2008, with its headquarters in South San Francisco in California. Stemcentrx operates as a subsidiary of AbbVie as of June 1, 2016.
STEMCENTRX
Industry:
Alternative Medicine Biotechnology Health Diagnostics Pharmaceutical Therapeutics
Founded:
2008-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.stemcentrx.com
Total Employee:
101+
Status:
Active
Contact:
16504910116
Email Addresses:
[email protected]
Total Funding:
515.53 M USD
Technology used in webpage:
Domain Not Resolving SPF Google Maps Google Apps For Business GStatic Google Static Content Google Maps API Microsoft Azure DNS GoDaddy
Similar Organizations
Accent Therapeutics
Accent Therapeutics is a biopharmaceutical company.
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Cobra Biologics
Cobra Biologics is providing a biologics and pharmaceuticals service.
Guardian Pharmacy
Guardian Pharmacy is a pharmacy company provide outstanding client service to long-term care facilities.
Indiva
Indiva provide access to medical cannabis.
Labcyte
Labcyte is the maker of Echo Acoustic Liquid Handling systems for life sciences.
Malladi Drugs
Malladi Drugs is a pharmaceutical manufacturing company manufacturing medicines.
Nymox Pharmaceutical
Nymox Pharmaceutical is a biopharmaceutical company.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
TruTag Technologies
TruTag Technologies, Inc. provides product authentication and brand protection solutions.
Current Advisors List
Founder
Investors List
Sequoia Capital
Sequoia Capital investment in Series G - Stemcentrx
Artis Ventures (AV)
Artis Ventures (AV) investment in Series G - Stemcentrx
Fidelity
Fidelity investment in Series G - Stemcentrx
Founders Fund
Founders Fund investment in Series G - Stemcentrx
Silicon Valley Bank
Silicon Valley Bank investment in Series G - Stemcentrx
Oakhouse Partners
Oakhouse Partners investment in Series G - Stemcentrx
Sequoia Capital
Sequoia Capital investment in Series F - Stemcentrx
Capital Group
Capital Group investment in Series F - Stemcentrx
Artis Ventures (AV)
Artis Ventures (AV) investment in Series F - Stemcentrx
Founders Fund
Founders Fund investment in Series F - Stemcentrx
Official Site Inspections
http://www.stemcentrx.com
- Host name: p3nlhg216c1216.shr.prod.phx3.secureserver.net
- IP address: 184.168.177.1
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Stemcentrx"
StemCentRx Company Profile - Office Locations, Competitors
StemCentRx is a company that provides pharmaceutical services. It develops therapies that cure and significantly improve survival for cancer patients. The company provides disease-specific …See details»
Stemcentrx Company Profile 2024: Valuation, Investors …
Stemcentrx General Information Description. Provider of cancer research and drug-development services designed to find a new approach to treat cancer. The company's services provide therapies to eliminate cancer stem cells, which …See details»
Stemcentrx, Inc. - LinkedIn
Stemcentrx, Inc. | 5,296 followers on LinkedIn. Founded in 2008, Stemcentrx combines state-of-the-art research and GMP manufacturing capabilities. This has allowed us to advance from …See details»
Congratulations Stemcentrx - Medium
Apr 28, 2016 In March of 2011, ARTIS and our affiliates led the first institutional round of financing at Stemcentrx with a $18M investment in a total round of $25M. Stemcentrx represented everything we look ...See details»
Stemcentrx, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore Stemcentrx, Inc. with its drug pipeline, therapeutic area, technology platform, 4 clinical trials, 13 news, and 13 literature, Disease Domain:Neoplasms, Technology …See details»
Stemcentrx - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
This Startup That's Trying to Cure Cancer Just Got …
Apr 28, 2016 Stemcentrx was acquired for $5.8 billion in cash, but the deal could be worth more than $10 billion if the company hits successful milestones for clinical developments. Inc. Regionals Deadline ...See details»
AbbVie acquires Stemcentrx - 2016-04-28 - Crunchbase
Apr 28, 2016 Acquired Organization: Stemcentrx Stemcentrx provides pharmaceutical services. Acquiring Organization: AbbVie AbbVie is a pharmaceutical company that discovers, …See details»
Stemcentrx, Inc. - Founders Fund
Stemcentrx, Inc. is developing radical new therapies and diagnostics for patients with solid tumors.See details»
Why AbbVie Acquired Stemcentrx - Business Insider
Apr 28, 2016 Severino cited Stemcentrx's response rates to its lead drug, Rova-T, in people with hard-to-treat small cell lung cancer, along with the company's approach to targeting cancer …See details»
AbbVie bags a unicorn with $9.8B buyout deal for Stemcentrx
Apr 28, 2016 The pharma company put weeks of market buzz to rest today with the news that it is buying Stemcentrx, the little-known South San Francisco-based biotech pursuing a trendy …See details»
AbbVie Buying Cancer Drug Startup Stemcentrx for $10.2 Billion
Apr 28, 2016 AbbVie Buying Cancer Drug Startup Stemcentrx for $10.2 Billion. BY Dan Primack. Rankings. 100 Best Companies; Fortune 500; Global 500; Fortune 500 Europe; Most Powerful …See details»
Stemcentrx - Contacts, Employees, Board Members, Advisors
Organization. Stemcentrx . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Number of Board Member and Advisor …See details»
Stemcentrx bags $5.8 billion, even as Notch agent underwhelms
Jul 12, 2016 Stemcentrx showed that in a phase 1 trial of 74 patients with SCLC, 18% achieved either a complete response or a partial response with median overall survival at 4.6 months. In …See details»
AbbVie banishes the ghost of Stemcentrx - ApexOnco
Nov 30, 2023 AbbVie too saw the potential early, though the failure of Rova-T, an anti-DLL3 ADC, meant that the $5.8bn it had spent on Stemcentrx was money wasted. AbbVie has other …See details»
Stemcentrx and the New Startup Dispersion — The Information
Apr 29, 2016 Yesterday was an M&A bonanza with some $50 billion in deals announced, led by pharma and rounded out by Comcast’s acquisition of DreamWorks Animation. But the deal …See details»
Stemcentrx - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Organization. Stemcentrx . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Total Products Active 7. ... Stemcentrx has …See details»
The Last of Stemcentrx - Science | AAAS
Aug 30, 2019 Welcome to biotech, then. We're a long way from 1, and for a lot of good reasons. If by "success" you mean unloading the company for a very large payout, then Stemcentrx …See details»
Stemcentrx, Inc. (Stemcentrx, Inc.) - 药物管线_专利_临床试验_投融 …
了解Stemcentrx, Inc. (Stemcentrx, Inc.)公司的药物管线，治疗领域，技术平台，以及它的4项临床试验, 56篇新闻和6篇文献，疾病领域:肿瘤，技术平台:单克隆抗体，药 …See details»